BR112023017019A2 - Método para tratar um distúrbio atenuado por ativação de receptores muscarínicos, método para tratar psicose relacionada à demência em um paciente que precisa do mesmo e composição farmacêutica oral - Google Patents
Método para tratar um distúrbio atenuado por ativação de receptores muscarínicos, método para tratar psicose relacionada à demência em um paciente que precisa do mesmo e composição farmacêutica oralInfo
- Publication number
- BR112023017019A2 BR112023017019A2 BR112023017019A BR112023017019A BR112023017019A2 BR 112023017019 A2 BR112023017019 A2 BR 112023017019A2 BR 112023017019 A BR112023017019 A BR 112023017019A BR 112023017019 A BR112023017019 A BR 112023017019A BR 112023017019 A2 BR112023017019 A2 BR 112023017019A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- patient
- dementia
- attenuated
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163153095P | 2021-02-24 | 2021-02-24 | |
| US202163213998P | 2021-06-23 | 2021-06-23 | |
| PCT/US2022/017485 WO2022182733A1 (en) | 2021-02-24 | 2022-02-23 | Methods for treating disorders ameliorated by muscarinic receptor activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023017019A2 true BR112023017019A2 (pt) | 2023-11-07 |
Family
ID=83048440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023017019A BR112023017019A2 (pt) | 2021-02-24 | 2022-02-23 | Método para tratar um distúrbio atenuado por ativação de receptores muscarínicos, método para tratar psicose relacionada à demência em um paciente que precisa do mesmo e composição farmacêutica oral |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240156802A1 (https=) |
| EP (1) | EP4297732A4 (https=) |
| JP (1) | JP2024507367A (https=) |
| AU (1) | AU2022226157A1 (https=) |
| BR (1) | BR112023017019A2 (https=) |
| CA (1) | CA3209262A1 (https=) |
| IL (1) | IL305412A (https=) |
| TW (1) | TW202332443A (https=) |
| WO (1) | WO2022182733A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102408292B1 (ko) | 2018-09-28 | 2022-06-10 | 카루나 세러퓨틱스 인코포레이티드 | 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법 |
| EP4091607A1 (en) * | 2021-05-18 | 2022-11-23 | Karuna Therapeutics, Inc. | Methods for treating central nervous system disorders with muscarinic receptor activator xanomeline and antipsychotics |
| US12269818B2 (en) | 2023-04-24 | 2025-04-08 | Terran Biosciences Inc. | Analogs of xanomeline |
| WO2026064593A1 (en) * | 2024-09-20 | 2026-03-26 | Karuna Therapeutics, Inc. | Method and compositions relating to the treatment of neuro-degenerative and psychiatric diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010540454A (ja) * | 2007-09-21 | 2010-12-24 | アカディア ファーマシューティカルズ，インコーポレーテッド | ピマバンセリンと他の薬剤との併用投与 |
| KR102408292B1 (ko) * | 2018-09-28 | 2022-06-10 | 카루나 세러퓨틱스 인코포레이티드 | 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법 |
| CN120514706A (zh) * | 2019-11-18 | 2025-08-22 | 卡鲁娜治疗学有限公司 | 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法 |
| US20220370454A1 (en) * | 2021-05-18 | 2022-11-24 | Karuna Therapeutics, Inc. | Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics |
-
2022
- 2022-02-23 JP JP2023550610A patent/JP2024507367A/ja active Pending
- 2022-02-23 BR BR112023017019A patent/BR112023017019A2/pt unknown
- 2022-02-23 WO PCT/US2022/017485 patent/WO2022182733A1/en not_active Ceased
- 2022-02-23 CA CA3209262A patent/CA3209262A1/en active Pending
- 2022-02-23 IL IL305412A patent/IL305412A/en unknown
- 2022-02-23 EP EP22760321.4A patent/EP4297732A4/en active Pending
- 2022-02-23 AU AU2022226157A patent/AU2022226157A1/en active Pending
- 2022-02-24 TW TW111106823A patent/TW202332443A/zh unknown
-
2023
- 2023-08-23 US US18/454,177 patent/US20240156802A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4297732A4 (en) | 2025-03-26 |
| WO2022182733A1 (en) | 2022-09-01 |
| US20240156802A1 (en) | 2024-05-16 |
| CA3209262A1 (en) | 2022-09-01 |
| AU2022226157A1 (en) | 2023-09-14 |
| JP2024507367A (ja) | 2024-02-19 |
| TW202332443A (zh) | 2023-08-16 |
| EP4297732A1 (en) | 2024-01-03 |
| IL305412A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023017019A2 (pt) | Método para tratar um distúrbio atenuado por ativação de receptores muscarínicos, método para tratar psicose relacionada à demência em um paciente que precisa do mesmo e composição farmacêutica oral | |
| BR112021009595A2 (pt) | Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres | |
| BR112014031394A2 (pt) | composições e métodos para absorção transmucosa | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| BR112016002465A2 (pt) | terapia da combinação para o tratamento de câncer | |
| BR112012018022A2 (pt) | inibição de sinalização axl em terapia antimetastática. | |
| AR054141A1 (es) | Terapia combinada para el tratamiento de trastornos inmunoinflamatorios | |
| BR112012009250A2 (pt) | composição compreendendo conjugado anti-cd56-maitansinoide e uso da mesma | |
| BR112023004497A2 (pt) | Composto de fórmula química 1 ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica para o tratamento ou prevenção de câncer com uma mutação de egfr | |
| BR112022015972A2 (pt) | Combinação compreendendo alpelisibe e ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-idro-7h-benzo[7]anuleno-2-carboxílico | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112018068784A2 (pt) | método para o tratamento de leucemia | |
| BR112014023423A2 (pt) | terapia de combinação | |
| BR112021006318A2 (pt) | terapia de combinação para o tratamento de câncer | |
| BR112017008709A2 (pt) | tratamento ou prevenção da anemia em mamíferos não-humanos grávidos | |
| BR112015026631A2 (pt) | compostos ou sais farmaceuticamente aceitáveis dos mesmos e respectivos usos, composição farmacêutica e método para prevenir ou tratar diabetes melito em mamífero | |
| SG194735A1 (en) | Compositions and methods for treating cancer | |
| BR112022019338A2 (pt) | Tratamento preventivo de enxaqueca | |
| BR112014009141A8 (pt) | regime de dosagem para um modulador ou agonista do receptor s1p | |
| BR112023017999A2 (pt) | Obicetrapibe para tratamento de demências | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| BR112019008698A2 (pt) | método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica | |
| Wagner | Anxiety Disorders in Children and Adolescents: New Findings. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: KARUNA THERAPEUTICS, INC. (US) |